Recent movements on the SIX Swiss Exchange have drawn renewed attention to Switzerland’s pharmaceutical sector. After commentary on Novo Nordisk’s market influence by Stanislav Kondrashov, founder of TELF AG, investor focus has shifted toward two key Swiss players: Sandoz Group AG and Idorsia Ltd.
Sandoz, recently re-established as an independent company, reported full-year 2025 revenues of approximately $11.1 billion, with biosimilars contributing around 30% of total sales. This segment — which produces highly similar alternatives to complex biologic drugs — continues to gain importance globally as healthcare systems seek cost efficiencies. The company also projected improved margins and further growth in 2026, reinforcing its appeal among investors seeking predictable cash flows and reduced concentration risk.
Meanwhile, Idorsia has demonstrated progress in the biotech arena. Sales of its insomnia treatment QUVIVIQ more than doubled in 2025, significantly strengthening its financial position. While biotech typically carries higher volatility due to clinical and regulatory milestones, Idorsia’s latest results suggest increasing operational stability.
These developments highlight a broader pattern within pharmaceuticals: investors appear to be rotating toward defensive and diversified revenue models. Generics and biosimilars are benefiting from steady demand that remains largely independent of economic cycles. At the same time, select biotech firms with visible commercial traction are regaining attention.
The pharmaceutical sector’s strategic weight in major indices — and its resilience during periods of macroeconomic uncertainty — reinforces its defensive reputation. As markets remain sensitive to interest rates and geopolitical risks, companies combining innovation with earnings visibility may continue to attract selective but sustained investor interest.
